Książki

Offers critical reviews of important topics in medicinal chemistry together with an emphasis on topics in the biological sciences, which provide the basis for various therapies. This title covers findings related to cardiovascular, inflammation, and pulmonary diseases. It examines issues in oncology, from mTor inhibitors to drug targets.

Annual Reports in Medicinal Chemistry

Section I: Central Nervous System Diseases - ROBICHAUD







Voltage-Gated Calcium Channel Antagonists for the Central Nervous System

James C. Barrow and Joseph L. Duffy



Recent Developments in Glycine Transporter-1 Inhibitors

Christopher L. Cioffi, Shuang Liu and Mark A.Wolf



Modulators of Transient Receptor Potential Ion Channels

Rajagopal Bakthavatchalam and S. David Kimball



Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-species Pharmacologic Exposure-Response Relationships

Christopher L. Shaffer



Section II: Cardiovascular and Metabolic Diseases - STAMFORD



High Affinity Niacin Receptor GPR109A Agonists

Hong C. Shen and Steven L. Colletti



Recent Advances in Acetyl CoA Carboxylase (ACC) Inhibitors

Matthew P. Bourbeau, John G. Allen, and Wei Gu



Enzymatic Targets in the Triglyceride Synthesis Pathway

Dmitry O. Koltun and Jeff Zablocki



Inhibitors of HIF Prolyl Hydroxylases

Michael H. Rabinowitz, Terrance D. Barrett, Mark D. Rosen, Hariharan Venkatesan



Section III: Inflammation / Pulmonary / GI - BARRISH/Weinstein



Opioid Receptor Antagonists for Gastrointestinal Dysfunction

R. William Hipkin and Roland E. Dolle



CFTR Modulators for the Treatment of Cystic Fibrosis

Sabine Hadida, Frederick Van Goor and Peter D. J. Grootenhuis



Targeting B-cells in inflammatory disease

Kevin S. Currie



Modulators of Toll-Like Receptor (TLR) Signaling

Mark Spyvee, Lynn Hawkins, and Sally Ishizaka



Section IV: Oncology - McAlpine



Janus Kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasm (MPN)

Ashok V. Purandare, Matthew V. Lorenzi and Louis J. Lombardo



Development of poly(ADP-ribose)polymerase (PARP) inhibitors in oncology

Philip Jones



Epigenetic Targets and Cancer Drug Discovery

Patrick M. Woster, Ph.D



Section V: Infectious Diseases - Primeau



HIV-1 Integrase Strand Transfer Inhibitors

Brian A. Johns



Recent Advances in Drug Discovery for Neglected Tropical Diseases Caused by Infective Kinetoplastid Parasites

Robert T. Jacobs and Charles Ding



Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis

Vincent Gerusz



Section VI: Topics in Biology - LOWE



Back to the Plaque: Emerging Studies That Re-Focus Attention on the Neuritic Plaque in Alzheimer's Disease

Dr. Robert B. Nelson



Targeting Methyl Lysine

Stephen V. Frye, Tom Heightman and Jian Jin



Chemical Proteomic Technologies for Drug Target Identification

Kieran F. Geoghegan and Douglas S. Johnson



NIH Translational Programs for Assisting Pre-Clinical Drug Discovery and Development

Raj N. Misra



Section VII: Topics in Drug Design and Discovery - DESAI



Role of Physicochemical Properties and Lipophilic Ligand Efficiency (LipE or LLE) in addressing Drug Safety Risks

Martin P. Edwards and David A. Price



Reducing the Risk of Drug Attrition Associated with Physicochemical Properties

Paul D. Leeson and James R. Empfield



Compound Collection Enhancement and Paradigms for High Throughput Screening - an Update

Stevan W Djuric, Irini Akritopoulou-Zanze, Philip B Cox and Scott Galasinski



The Role of Fluorine in the Discovery and Optimization of CNS Agents: Modulation of Drug-Like Properties

Kevin J. Hodgetts, Kerry J. Combs, Amy M. Elder and Geraldine C. Harriman



Patents in Drug Discovery: Case Studies, Examples, and Simple Steps Medicinal Chemists Can Take to Protect Hard-Won Intellectual Property

Charles J. Andres, Jr. and Richard L. Treanor



Section VIII: Trends and Perspectives



To Market, To Market - 2009



Shridhar Hegde and Michelle Schmidt